Division of Gastroenterology

John Marshall


Professor, Department of Medicine

Director, Division of Gastroenterology

Member, Farncombe Family Digestive Health Research Institute

Head, Clinical Research for the Division of Gastroenterology




Education and Professional Standing

Dr. Marshall is a Professor of Medicine at McMaster University and Chief of Service for Gastroenterology at Hamilton Health Sciences in Hamilton, Ontario. He completed his B.A. and M.D. at Queen’s University, and then undertook his residency training and M.Sc. in Clinical Epidemiology & Biostatistics at McMaster University. He is a Full Member of the Farncombe Family Digestive Health Research Institute. His publications include over 180 academic papers and book chapters and over 200 abstracts. He is currently Co-Editor-in-Chief of the Canadian Journal of Gastroenterology and Hepatology, an Associate Editor of ACP Journal Club and Evidence-Based Medicine, an Editorial Board Member for the Journal of Crohn’s and Colitis and Clinical Gastroenterology and Hepatology, and an Editor for the Cochrane Collaboration Inflammatory Bowel Disease and Functional Bowel Disorders Review Group. Honours include the Canadian Association of Gastroenterology (CAG) Young Investigator Award (2008), the CAG Young Educator Award (2006) and Fellowship in the American Gastroenterological Association (2007). Dr. Marshall’s clinical and research interests include inflammatory bowel disease, post-infectious irritable bowel syndrome, gastrointestinal bleeding, endoscopy, clinical trials, clinical epidemiology, health outcomes and health economics.

Selected Publications

  1. Marshall JK, Thabane M, Garg AX, Clark W, Salvadori M, Collins SM. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 2006;131:445-50.
  2. Marshall JK, Thabane M, Borgaonkar M, James C. Post infectious irritable bowel syndrome following a foodborne outbreak of acute gastroenteritis attributed to a viral pathogen.  Clin Gastroenterol Hepatol 2007;5:457-60.
  3. Marshall JK, Thabane M, Steinhart AH, Newman J, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission of ulcerative colitis. Cochrane Database Syst Rev 2010;CD004115.
  4. Villani AC, Lemire M, Thabane M, Geneau G, Belisle A, Garg AX, Clark WF, Moayyedi P, Collins SM, Franchimont D, Marshall JK.  Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis.
  5. Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM. Eight-year prognosis of post-infectious irritable bowel syndrome following waterborne bacterial dysentery. Gut 2010;59:605-11. Commentary: Wang HW, Chang L. The Walkerton outbreak revisited at year 8: predictors, prevalence and prognosis of post-infectious IBS. Gastroenterology 2011;140:726-8.
  6.  Greenspoon J, Barkun A, Bardou M, Chiba N, Leontiadi s GI, Marshall JK, Metz DC, Romagnuolo J, Sung J, International Consensus Upper Gastrointestinal Bleeding Conference Group. Management of patients with non-variceal upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2012;10:234-9.
  7. Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for maintaining remission of distal ulcerative colitis. Cochrane Database Syst Rev 2012(11):CD004118.
  8. Marshall JK, Otley AR, Afif W, Bernstein CN, Hookey L, Leontiadis G, Panaccione R, Bressler B. Canadian Association of Gastroenterology position statement on the use of thiopurines in the treatment of inflammatory bowel disease. Can J Gastroenterol Hepatol 2014;28:371-2.
  9.  Moayyedi P, Surette MG, Wolfe M, Kim PT, Taraschi R, Libertucci J, Armstrong D, Marshall JK, Kassam Z, Reinisch W, Lee C. A randomized placebo controlled trial of fecal microbial therapy in ulcerative colitis: a mandate for further clinical trials. Gastroenterology 2015;149:102-9.
  10. Narula N, Fine M, Colombel JF, Marshall JK, Reinisch W. Systematic review: sequential rescue therapy in severe ulcerative colitis: do the benefits outweigh the risks? Inflamm Bowel Dis 2015;21:1683-94.
  11. Bressler B*, Marshall JK*, Bernstein CN, Bitton A, Jones J, Leontiadis GL, Panaccione R, Steinhart AH, Tse F, Feagan B, Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of ulcerative colitis: the Toronto Consensus. Gastroenterology 2015;148:1035-58 (*co-principal authors).
  12. Narula N, Marshall JK, Colombel JF, Leontiadis G, Williams JG, Muqtadir Z, Reinisch W. Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids. Am J Gastroenterol 2016 [in press].
  13. Chande N, Marshall JK, Seow C, Sandborn WJ, Parker CE, Nelson S, Feagan BG. New applications for traditional drugs in inflammatory bowel disease: what do Cochrane reviews tell us?  Inflamm Bowel Dis 2015;21:2948-57.
  14. Fallone CA, Chiba N, Veldhuyzen van Zanten S, Fischer L, Gisbert J, Hunt R, Jones N, Render C, Leontiadis G, Moayyedi P, Marshall JK. Clinical practice guidelines for the treatment of Helicobacter pylori infection: the Toronto consensus. Gastroenterology 2016 [in press].